Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
Did patients with locally advanced or metastatic breast cancer realize improvements in progression-free survival after treatment with this triple combination therapy?
Navitoclax used in combination with EGFR-targeted ADCs could present a potential new treatment option for EGFR-expressing triple-negative breast cancer.
Recent developments in our understanding of quadruple-negative breast cancer could have important implications for therapy development and future research.
Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry.
Correction to: Progesterone receptor membrane component 1 regulates lipid homeostasis and drives oncogenic signaling resulting in breast cancer progression.
Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy.
Mission Statement:
Breast Cancer Research
is a multidisciplinary journal edited by Bruce Ponder, Lewis Chodosh, Stephen Johnston and an international editorial board.
